Westover Capital Advisors LLC Sells 3,446 Shares of Thermo Fisher Scientific Inc. $TMO

Westover Capital Advisors LLC lessened its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 36.2% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 6,065 shares of the medical research company’s stock after selling 3,446 shares during the period. Westover Capital Advisors LLC’s holdings in Thermo Fisher Scientific were worth $2,459,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Flossbach Von Storch SE increased its position in Thermo Fisher Scientific by 93.0% during the 2nd quarter. Flossbach Von Storch SE now owns 2,727,021 shares of the medical research company’s stock valued at $1,105,698,000 after purchasing an additional 1,314,182 shares during the period. Nuveen LLC bought a new stake in shares of Thermo Fisher Scientific in the 1st quarter valued at $532,360,000. Mitsubishi UFJ Asset Management Co. Ltd. raised its stake in Thermo Fisher Scientific by 29.5% during the second quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,257,424 shares of the medical research company’s stock worth $915,295,000 after buying an additional 514,399 shares during the last quarter. EdgePoint Investment Group Inc. bought a new stake in Thermo Fisher Scientific during the first quarter valued at $172,139,000. Finally, Lindsell Train Ltd raised its position in shares of Thermo Fisher Scientific by 68.0% in the 2nd quarter. Lindsell Train Ltd now owns 854,612 shares of the medical research company’s stock worth $346,511,000 after acquiring an additional 345,822 shares in the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, VP Lisa P. Britt sold 10,225 shares of Thermo Fisher Scientific stock in a transaction dated Friday, November 7th. The shares were sold at an average price of $571.62, for a total value of $5,844,814.50. Following the completion of the transaction, the vice president owned 14,145 shares in the company, valued at $8,085,564.90. This trade represents a 41.96% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Marc N. Casper sold 17,104 shares of the company’s stock in a transaction that occurred on Friday, October 24th. The shares were sold at an average price of $573.54, for a total transaction of $9,809,828.16. Following the sale, the chief executive officer owned 113,762 shares in the company, valued at $65,247,057.48. The trade was a 13.07% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders have sold 52,140 shares of company stock valued at $29,104,464. 0.33% of the stock is currently owned by corporate insiders.

Thermo Fisher Scientific Stock Performance

TMO opened at $567.49 on Tuesday. The company has a market cap of $213.21 billion, a price-to-earnings ratio of 32.78, a PEG ratio of 3.27 and a beta of 0.82. The company’s fifty day moving average price is $529.51 and its two-hundred day moving average price is $469.36. Thermo Fisher Scientific Inc. has a 1-year low of $385.46 and a 1-year high of $610.97. The company has a current ratio of 1.50, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Wednesday, October 22nd. The medical research company reported $5.79 earnings per share for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion for the quarter, compared to analysts’ expectations of $10.90 billion. During the same period in the previous year, the company earned $5.28 earnings per share. The firm’s revenue for the quarter was up 4.9% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. On average, analysts expect that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific announced that its board has authorized a share buyback program on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to reacquire up to 2.4% of its shares through open market purchases. Shares buyback programs are often a sign that the company’s management believes its stock is undervalued.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, January 15th. Shareholders of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date of this dividend is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is 9.94%.

Analyst Ratings Changes

TMO has been the subject of several recent analyst reports. Royal Bank Of Canada set a $561.00 target price on Thermo Fisher Scientific and gave the stock an “outperform” rating in a research note on Tuesday, September 2nd. JPMorgan Chase & Co. lifted their price objective on shares of Thermo Fisher Scientific from $600.00 to $650.00 and gave the company an “overweight” rating in a research note on Thursday, October 9th. Leerink Partners increased their target price on shares of Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. Citigroup raised their price target on shares of Thermo Fisher Scientific from $500.00 to $580.00 and gave the stock a “neutral” rating in a report on Thursday, October 23rd. Finally, Cowen restated a “buy” rating on shares of Thermo Fisher Scientific in a research note on Thursday, October 23rd. Nineteen analysts have rated the stock with a Buy rating and five have given a Hold rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $601.65.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.